2023年5月29日

新泽西州普林斯顿| 2023年5月29日东部时间上午10:30 Longevica,新泽西由科学推动公司致力于揭露延长寿命的机制,积极寻求资金支持其开创性的研究。专用的一个科学家小组和慈善家,Longevica依靠科学数据来源于基本实验和综合模型来驱动它的使命。成立于2009年,Longevica的远景是减缓衰老,推迟衰老相关疾病,并最终消除它们。Longevica的研究采用反向的方法旨在确定延长寿命的机制。公司开始着手一项雄心勃勃的涉及最大的一系列化合物良好的药理实验小鼠,使其成为最大的研究长寿的老鼠。研究在加州著名的杰克逊实验室进行的,涉及20000年长寿的雌性老鼠的影响并分析了1033年药物化合物,例如镁、阿司匹林等。据该公司介绍,实验证明是一场彻底的胜利。此外,通过广泛的大数据分析,Longevica识别两个特定类的化合物的共有62家与延长寿命,体现出统计上显著相关。这一突破提供至关重要的见解机制延长寿命的存在。建筑在这些非凡的发现,Longevica团队专门随后六年的研究这两个化合物类。 Their research focused on understanding the mechanisms of action and the historical applications of these compounds in human medicine. As a result, the team in 2019-2021 established valid hypotheses regarding two mechanisms of life extension, with further details currently being specified. Both mechanisms aim to combat harmful compounds accumulation, leading to improved health and extended lifespan. These results were a surprise to all that were part of this experiment, truly showing the lack of knowledge and expectations we have regarding evolution and length of lifespan. The core paradigm of Longevica's life extension approach revolves around reducing “toxins”, thereby mitigating age-related diseases and promoting longevity. Following 14 years of research including their mice experiment and 15 million dollars in financing, Longevica is now poised to complete its aging research. “The truth is that we as humanity have a mission. After years of research, we still don’t understand the mechanisms that would enable us to move the survival curve to the right, meaning extending life span, even in mice. This research will be able to answer many if not all questions regarding life extension, bringing it out of a world of myth into reality. We plan on being able to turn our focus towards human life extension in our future research.” says Alexander Chikunov, founder of Longevica who provided all funds for this stage of research. Media contact: